Overview:
Payer coverage and economic value continue to be critical factors in determining whether genomic medicine (GM) is appropriately and efficiently implemented into clinical care and health policies. However, genomic tests are now emerging that present particularly difficult challenges for coverage and value determinations.

This study will provide unique insights by examining (a) multiple clinical scenarios that allow us to compare disease management to screening tests and to compare tests for the most common application of GM (cancer) with uses that have been less common but are increasing (e.g., coronary artery disease), and (b) both coverage and economic value so that we can understand how these are interrelated.

Objectives:
Our objective is to assess payer coverage decisions and the economic value of two types of emerging genomic tests for disease management and screening: cell-free DNA (cfDNA) and tests based on Polygenic Risk Score (PRS).

Aim 1: Examine which cfDNA and PRS tests are covered and why using (a) systematic evidence reviews of payer coverage policies and (b) structured interviews with payers on how they consider evidence and make coverage decisions.

Aim 2: Understand the economic value of cfDNA and PRS tests by taking a patient-centered approach, addressing key methodological challenges, and identifying gaps in evidence.

Aim 3: Compare evidence needs for payer coverage (Aim 1) and economic value assessment (Aim 2) across clinical scenarios and generalize our findings on evidence needs to other emerging clinical scenarios, considering patient access and stakeholder perspectives.

PI: Kathryn Phillips, UCSF
Key Collaborators: UCSF (Phillips, Douglas, Jansen), Executive Frameworks (Trosman)
Scientific Advisory Board and Other Collaborators: Arias, Deverka, Cheng, Gray, Khoury, Koenig, Kurian, Lin, Maddala, Neumann, Scheuner, Weldon, Ziv.
Funding: National Human Genome Research Institute (NHGRI); grant number R01-HG011792